Last update 01 Jun 2024

Inaticabtagene Autoleucel

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
Anti-CD19 CAR-T cell therapy (Heyuan Biotech), Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (Juventas Cell), 抗CD19嵌合抗原受体T细胞 (CAR-T)疗法 (天津合源生物)
+ [8]
Target
Mechanism
CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors)
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Priority Review (CN), Breakthrough Therapy (CN), Conditional marketing approval (CN)
Login to view First Approval Timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Refractory B Acute Lymphoblastic Leukemia
CN
08 Nov 2023
Recurrent B Acute Lymphoblastic Leukemia
CN
07 Nov 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CD19-positive B-cell acute lymphoblastic leukemiaPhase 2
CN
07 Feb 2023
Pre B-cell acute lymphoblastic leukemiaPhase 2
CN
07 Feb 2023
CD19 positive Acute Lymphoblastic LeukemiaPhase 2
CN
24 Dec 2020
Non-Hodgkin's lymphoma refractoryPhase 2
CN
26 Oct 2020
Recurrent Non-Hodgkin LymphomaPhase 2
CN
26 Oct 2020
Non-Hodgkin LymphomaPhase 2--
Autoimmune Haemolytic AnaemiasPhase 1
CN
04 Feb 2024
Systemic Lupus ErythematosusPhase 1
CN
14 Dec 2021
CD19 positive Non-Hodgkin LymphomaPhase 1
CN
15 Jan 2020
Diffuse non-Hodgkin's lymphomaPhase 1
CN
15 Jan 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
16
Fludarabine+Cyclophosphamide+CNCT19
byeljaanhu(gpvhccjdjm) = qndwirtrbx dkmfplzoyq (elotxmosmu )
Positive
15 Nov 2022
Phase 1/2
18
wiznonwndu(scyfsnyoqr) = uwbtkwizbw pgqfkxhpik (ssjdsrevld )
Positive
15 Nov 2022
Phase 2
36
(OCR within 3 Months)
qaxgpcneil(uwlasblbye) = locxhzlzhn anetyecybd (bwetdecdnx, 70.5 - 95.3)
Positive
15 Nov 2022
(OCR at the end of Month 3)
qaxgpcneil(uwlasblbye) = dgboufozdp anetyecybd (bwetdecdnx, 46.8 - 81.4)
Phase 1
22
bfmexjhnrz(dqgoqibgoh) = qyrutgngbn jdpzbdylnh (coppoqrjiu )
Positive
07 Sep 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free